Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

Table 2 Clinical findings of CML patients responsive to imatinib therapy and a potential biomarker at the molecular response

Total No	Age (year)	Duration on imatinib (month)	IRIS molecular response (*BCR-ABL1* ^ISa)	Relative expression^b of hsa-miR-181a-5p (fold regulation) (collectively = 2.14 down-regulation)
16	25–75	26–122	MMR (≤ 0.1% or > 3-log reduction)	−5.5987 to 1.2789
12	40–71	20–131	MR⁴ (≤ 0.01% BCR-ABL1^IS or undetectable with 10,000–31,999 ABL1 transcripts)	−8.664 to − 1.0906
2	32–54	24–50	MR^4.5 (≤ 0.0032% BCR-ABL1^IS or undetectable with 32,000–99,999 ABL1 transcripts)	− 2.5939 and − 1.7594
30	25-75^c (47.87 ± 13.23)^d	20-131^c (68.63 ± 31.95)^d

ISSN: 1471-2407